Bildkälla: Stockfoto

AroCell Q4: Steady operations - Redeye

Redeye notes a quarter showing continuing sales growth for AroCell with good cost control. We slightly up our sales estimate for 2023e and lower our WACC following a review or Redeye Quality Rating, resulting in upwards changes to our fair value range.

Redeye notes a quarter showing continuing sales growth for AroCell with good cost control. We slightly up our sales estimate for 2023e and lower our WACC following a review or Redeye Quality Rating, resulting in upwards changes to our fair value range.
Börsvärldens nyhetsbrev
ANNONSER